Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLACE: regorafenib + pembrolizumab vs TACE/TARE in intermediate-stage HCC beyond up-to-7
2022-501969-42-00Phase 3Completed
- Sponsor
- Translational Research In Oncology
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and regorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Translational Research In Oncology. Primary endpoint: Progression-free survival (PFS) per mRECIST (investigator assessment). Started Nov 2023; status: completed.
02
Drugs
pembrolizumabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-501969-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501969-42-00.